Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company specializes in antibody engineering technology to develop treatments for rare autoimmune conditions. Its lead product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by subsequent approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address significant unmet medical needs in the field of immunology.
OncoVerity is dedicated to enhancing the development of cusatuzumab, a novel anti-CD70 antibody, while also advancing medical research through its innovative platform. This platform focuses on creating clinical and single-cell multi-omics databases aimed at improving the lives of cancer patients. By bridging the gap between research and healthcare delivery, OncoVerity seeks to integrate advanced multi-omic data science into drug development. The company is committed to providing effective solutions for patients with unmet medical needs, ultimately aiming to deliver cutting-edge treatments to those battling cancer.
Food and Drug Administration - Priority Review Voucher
Acquisition in 2022
Priority Review voucher is an e-marketing application for efgartigimod.
OncoVerity
Venture Round in 2022
OncoVerity is dedicated to enhancing the development of cusatuzumab, a novel anti-CD70 antibody, while also advancing medical research through its innovative platform. This platform focuses on creating clinical and single-cell multi-omics databases aimed at improving the lives of cancer patients. By bridging the gap between research and healthcare delivery, OncoVerity seeks to integrate advanced multi-omic data science into drug development. The company is committed to providing effective solutions for patients with unmet medical needs, ultimately aiming to deliver cutting-edge treatments to those battling cancer.
Halozyme Therapeutics
Post in 2019
Halozyme Therapeutics, Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of innovative therapies that target the extracellular matrix, particularly through its proprietary ENHANZE drug delivery technology. This technology utilizes a patented recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of various injectable biologics and small molecules. Halozyme’s product portfolio includes Hylenex recombinant, which aids in fluid administration and enhances the absorption of injected drugs. The company is advancing a range of product candidates for conditions such as breast cancer, non-Hodgkin lymphoma, multiple sclerosis, and various autoimmune diseases. Additionally, Halozyme collaborates with major pharmaceutical companies to integrate its technology into therapeutic biologics. The company was founded in 1998 and operates internationally, primarily in the United States and Switzerland.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.